A Phase 1/2, First-in-Human, Multicenter, Open-Label Study of SQZ-eAPC-HPV as Monotherapy and in Combination with Immune Checkpoint Inhibitor(s) in Patients with HPV16+ Recurrent, Locally Advanced, or Metastatic Solid Tumors

This Study is
No Longer Enrolling

Details
Age

Adult

Eligibility

Histologically confirmed incurable or metastatic solid tumor (including but not limited to cervical and head and neck tumors) that are HPV16+ as determined by histological or HPV16 molecular analysis.

Type of Study

Treatment

Locations

CTRC Inpatient
University of Colorado Hospital

Study ID

Protocol Number: 22-0228

More information available at ClinicalTrials.gov: NCT05357898

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers